Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Abstract Background Cabozantinib was approved by the European Medicines Agency and the Federal Drug Administration as an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival and progression-free survival compared with placebo. We evaluated the cost-effectiven...

Full description

Bibliographic Details
Main Authors: Maximilian Sieg, Michael Hartmann, Utz Settmacher, Habibollah Arefian
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Gastroenterology
Subjects:
Hepatocellular carcinoma
Cost-effectiveness
Cabozantinib
Second-line therapy
Online Access:http://link.springer.com/article/10.1186/s12876-020-01241-y

Internet

http://link.springer.com/article/10.1186/s12876-020-01241-y

Similar Items